Current Report Filing (8-k)
July 26 2017 - 04:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event
reported): July 24, 2017
NOVAVAX, INC.
(Exact name of registrant as specified in
charter)
Delaware
|
|
0-26770
|
|
22-2816046
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
20 Firstfield Road
Gaithersburg, Maryland 20878
(Address of Principal Executive Offices,
including Zip Code)
(240) 268-2000
(Registrant’s telephone number, including
area code)
(Former name or
former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
¨
If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
Topline RSV F Vaccine Data from
Phase 2 Clinical Trial in Older Adults
On July 24,
2017, Novavax, Inc. (the “Company”) issued a press release announcing topline data from the Company’s Phase 2
safety and immunogenicity trial of its RSV F Vaccine in older adults. A copy of this press release is attached as Exhibit 99.1
to this Current Report on Form 8-K and incorporated herein by reference.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
Exhibit
No.
|
|
Description
|
|
|
|
|
99.1
|
|
Press release, dated July 24, 2017, regarding the Company’s topline RSV F Vaccine data from its Phase 2 clinical trial in older adults.
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
Novavax, Inc.
(Registrant)
|
|
|
|
|
|
|
Date: July 26, 2017
|
|
|
|
By:
|
|
/s/ John A. Herrmann III
|
|
|
|
|
|
|
|
Name:
|
|
John A. Herrmann III
|
|
|
|
|
|
|
|
Title:
|
|
Senior Vice President, General Counsel and
Corporate Secretary
|
|
|
|
|
|
|
|
|
|
|
|
EXHIBIT INDEX
Exhibit
No.
|
|
Description
|
|
|
|
|
99.1
|
|
Press release, dated July 24, 2017, regarding the Company’s topline RSV F Vaccine data from its Phase 2 clinical trial in older adults.
|
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Mar 2023 to Mar 2024